Polypharmacy and medication usage patterns in hypertensive patients: Findings from the Pars Cohort Study.

Autor: Zare P; MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran., Poustchi H; Liver and Pancreatobiliary Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Mohammadi Z; Liver and Pancreatobiliary Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Mesgarpour B; Research and Technology, National Institute for Medical Research and Development (NIMAD), Tehran, Iran., Akbari M; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: Akbari.mr96@gmail.com., Kamalipour A; Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California, San Diego, CA, USA., Abdipour-Mehrian SR; Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran., Hashemi ES; MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Ghamar-Shooshtari A; MPH Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Ophtalmology Resident of Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran., Hosseini SA; Postdoctoral Researcher, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Malekzadeh R; Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran., Bazrafshan Drissi H; Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Malekzadeh F; Digestive Diseases Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran., Molavi Vardanjani H; MPH Department, School of Medicine, Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: hosseinmolavi@ymail.com.
Jazyk: angličtina
Zdroj: Research in social & administrative pharmacy : RSAP [Res Social Adm Pharm] 2024 Nov; Vol. 20 (11), pp. 1038-1046. Date of Electronic Publication: 2024 Aug 02.
DOI: 10.1016/j.sapharm.2024.07.006
Abstrakt: Polypharmacy, defined here as the concomitant use of five or more medications, is a significant health issue, particularly affecting individuals with chronic diseases like hypertension (HTN). To compare individuals with and without HTN in term of polypharmacy, and to investigate correlates of polypharmacy and medication use patterns in individuals with HTN in southwest Iran. This cross-sectional study used the baseline data of 9270 participants of the Pars Cohort Study (PCS) with a mean age of 52.6 ± 9.7 years. Poisson multivariable modeling was applied to identify correlates of polypharmacy, and Lexicomp® was used to assess drug-drug interactions. Anatomical Therapeutic Chemical classification was used to describe the pattern of medication use. The prevalence of polypharmacy in individuals without hypertension was 4.7 % (4.2%-5.2 %) vs. 23.7 % (22.1%-25.3 %) in individuals with hypertension (P < 0.001). Individuals with hypertension from middle-high socioeconomic status (SES) had a 1.51-fold higher prevalence of polypharmacy than vs. low SES. Those with more than three comorbidities had a 5.18 times higher prevalence of polypharmacy than those with isolated hypertension. Calcium channel blockers were the most common antihypertensives (20.9 %). In terms of drug-drug interactions, type C interactions were most prevalent among participants with hypertension and polypharmacy (76.0 %). Our findings imply a fairly high prevalence of polypharmacy and drug-drug interactions among individuals with hypertension; to tackle this issue, we recommend a national pharmacovigilance system, training programs for primary care physicians, public education and awareness campaigns, drug-checking campaigns, targeted screenings to alter modifiable risk factors, and the use of safe combination pills.
Competing Interests: Declaration of competing interest The authors have no relevant financial or non-financial interests to disclose.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: